Hikma Pharmaceuticals Public annual net debt
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Net Debt Growth & History (HIK)
Hikma Pharmaceuticals Public's net debt was $1.39B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.39B | $269.0M | +24.06% |
| 2024 | 2024-12-31 | $1.12B | $132.0M | +13.39% |
| 2023 | 2023-12-31 | $986.0M | −$27.0M | −2.67% |
| 2022 | 2022-12-31 | $1.01B | $593.0M | +141.19% |
| 2021 | 2021-12-31 | $420.0M | −$189.0M | −31.03% |
| 2020 | 2020-12-31 | $609.0M | — | — |
Hikma Pharmaceuticals Public quarterly net debt
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.69B | $372.0M | +28.14% |
| Q4 2025 | 2025-12-31 | $1.39B | $269.0M | +24.06% |
| Q2 2025 | 2025-06-30 | $1.32B | — | — |
| Q4 2024 | 2024-12-31 | $1.12B | — | — |
Hikma Pharmaceuticals Public net debt trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's net debt increased from $609.0M to $1.39B, a change of $778.0M. The latest reported quarter, Q2 2026, shows $1.69B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...